Nucleophilic addition to 2,3-pyridyne and synthesis of benzonaphthyridinones
摘要:
A study of the nucleophilic addition of amines to 2,3-pyridyne has been carried out. 2-Aminopyridines have been generated exclusively. A series of benzonaphthyridinones have been synthesized by reacting 2,3-pyridyne and o-aminobenzoates. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT LA PROTEINE KINASE-2 ACTIVEE PAR LA PROTEINE KINASE ACTIVEE PAR DES AGENTS MITOGENES
申请人:PHARMACIA CORP
公开号:WO2004058762A1
公开(公告)日:2004-07-15
Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.
MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS
申请人:Pharmacia Corporation
公开号:EP1572693A1
公开(公告)日:2005-09-14
Nucleophilic addition to 2,3-pyridyne and synthesis of benzonaphthyridinones
作者:Yuesi Fang、Richard C. Larock
DOI:10.1016/j.tet.2012.02.002
日期:2012.4
A study of the nucleophilic addition of amines to 2,3-pyridyne has been carried out. 2-Aminopyridines have been generated exclusively. A series of benzonaphthyridinones have been synthesized by reacting 2,3-pyridyne and o-aminobenzoates. (C) 2012 Elsevier Ltd. All rights reserved.
Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
申请人:Pharmacia Corporation
公开号:US20040209897A1
公开(公告)日:2004-10-21
Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.